Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
We retrospectively compared the outcomes of 166 patients with hematological malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) using ATG-Thymoglobulin (ATG-T) at 10 mg/kg or ATG-Fresenius (ATG-F) at 20 mg/kg. Propensity score matching (PSM) analysis was applied, with 44 patients assigned to each group. The ATG-T group showed a trend toward a higher incidence of bacterial infections (72.7% vs. 65.9%, P = 0.064). Additionally, the ATG-T group had a significantly higher incidence of other viral infections, including BK virus and herpes zoster virus (40.9% vs. 15.9%, P = 0.003), compared to the ATG-F group. Furthermore, the ATG-F group experienced a lower incidence of high fever (4.5% vs. 50.0%, P < 0.001) and reduced ATG treatment costs [¥ 45100 (28700-82000) vs. ¥ 56250 (38000-85000), P < 0.001] compared to ATG-T. The incidences of acute GVHD, grade III-IV aGVHD, grades of aGVHD, chronic GVHD, 3-year overall survival (OS), transplantation-related mortality (TRM), non-relapse mortality (NRM), disease-free survival (DFS), and GVHD-free and relapse-free survival (GRFS) were similar between the ATG-T and ATG-F groups. In conclusion, our study suggests that ATG-F is superior to ATG-T in terms of viral infections, fever rate, and treatment cost.